research Skin Commensal Antigens: Taking the Road Less Traveled
Skin bacteria can help wound healing by activating certain immune cells.
Search
forLearn
0 / 0 results — no results
Research
5 / 822 results research JAK-STAT1 as Therapeutic Target for EGFR Deficiency-Associated Inflammation and Scarring Alopecia
Targeting JAK-STAT1 can reduce inflammation and promote hair growth in conditions linked to EGFR deficiency.
research Scarring Hair Follicle Destruction Is Driven by the Collapse of EGFR-Protected JAK-STAT1-Sensitive Stem Cell Immune Privilege
A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.
research Maintenance of Barrier Tissue Integrity by Unconventional Lymphocytes
Unconventional lymphocytes are important for quick immune responses and healing of skin and mucosal barriers.
research Biotechnological Applications of Mushrooms Under the Water-Energy-Food Nexus: Crucial Aspects and Prospects from Farm to Pharmacy
Mushrooms offer benefits for food, energy, and water security, and have potential uses in health and environmental applications.
Community Join
5 / 10 resultscommunity July 1st - Early H2 - Breezula
Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.
community What has happened to Breezula?
Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.
community Breezula(CB)Phase3Results Date
Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.
community New Breezula Update ( I think)
Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.
community Possibility of updates or more information on the pp405
The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.